Planning Directions Inc. Raises Holdings in Pfizer Inc. (NYSE:PFE)

Planning Directions Inc. raised its holdings in shares of Pfizer Inc. (NYSE:PFE) by 9.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 9,952 shares of the biopharmaceutical company’s stock after purchasing an additional 868 shares during the period. Planning Directions Inc.’s holdings in Pfizer were worth $431,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of PFE. Evolution Wealth Advisors LLC purchased a new stake in Pfizer during the 2nd quarter valued at $34,000. Winch Advisory Services LLC boosted its stake in Pfizer by 69.6% during the 4th quarter. Winch Advisory Services LLC now owns 819 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 336 shares during the last quarter. Ruggie Capital Group purchased a new stake in Pfizer during the 4th quarter valued at $44,000. Karp Capital Management Corp purchased a new stake in Pfizer during the 4th quarter valued at $53,000. Finally, HMS Capital Management LLC purchased a new stake in Pfizer during the 2nd quarter valued at $71,000. Institutional investors and hedge funds own 71.82% of the company’s stock.

In related news, EVP Frank A. Damelio sold 153,184 shares of the firm’s stock in a transaction on Tuesday, July 2nd. The stock was sold at an average price of $44.09, for a total value of $6,753,882.56. Following the transaction, the executive vice president now directly owns 489,647 shares of the company’s stock, valued at approximately $21,588,536.23. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Pfizer Inc bought 50,000 shares of the firm’s stock in a transaction that occurred on Monday, May 13th. The stock was bought at an average cost of $17.00 per share, for a total transaction of $850,000.00. The disclosure for this purchase can be found here. 0.09% of the stock is currently owned by company insiders.

Several equities analysts have recently weighed in on PFE shares. JPMorgan Chase & Co. set a $46.00 price target on Pfizer and gave the company a “neutral” rating in a report on Monday, July 29th. Barclays reissued a “hold” rating and set a $41.00 price target on shares of Pfizer in a report on Thursday, May 9th. Goldman Sachs Group reissued a “buy” rating and set a $49.00 price target on shares of Pfizer in a report on Monday, June 17th. Zacks Investment Research raised Pfizer from a “sell” rating to a “hold” rating in a report on Wednesday, April 10th. Finally, Credit Suisse Group started coverage on Pfizer in a report on Monday, July 15th. They set a “hold” rating and a $47.00 price target on the stock. Fifteen investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $46.44.

Pfizer stock traded down $0.25 during trading on Friday, reaching $38.00. The company had a trading volume of 27,652,919 shares, compared to its average volume of 28,194,710. Pfizer Inc. has a 52 week low of $37.68 and a 52 week high of $46.47. The business’s 50-day moving average is $42.85. The stock has a market capitalization of $212.67 billion, a price-to-earnings ratio of 12.67, a price-to-earnings-growth ratio of 3.05 and a beta of 0.63. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.54 and a quick ratio of 1.27.

Pfizer (NYSE:PFE) last announced its earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 EPS for the quarter, topping the Zacks’ consensus estimate of $0.75 by $0.05. Pfizer had a return on equity of 27.57% and a net margin of 23.58%. The company had revenue of $13.26 billion for the quarter, compared to analysts’ expectations of $13.43 billion. During the same period last year, the firm earned $0.77 EPS. Pfizer’s revenue for the quarter was down 1.5% compared to the same quarter last year. On average, sell-side analysts forecast that Pfizer Inc. will post 2.8 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, August 2nd will be issued a $0.36 dividend. The ex-dividend date of this dividend is Thursday, August 1st. This represents a $1.44 dividend on an annualized basis and a yield of 3.79%. Pfizer’s dividend payout ratio is currently 48.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

See Also: How to Invest in Marijuana Stocks

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.